@article{c617ed9270b1438da73fccfebdabe622,
title = "Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial",
keywords = "aged, aspirin, coronary artery disease, diagnosis, heart failure, primary prevention",
author = "Zhen Zhou and Mark Nelson and Ernst, {Michael E.} and Christopher Reid and John McNeil and Andrew Tonkin",
note = "Funding Information: The ASPREE trial (Aspirin in Reducing Events in the Elderly) was supported by grants from the National Institute on Aging and the National Cancer Institute at the National Institutes of Health (U01AG029824), the National Health and Medical Research Council of Australia, and Monash University and the Victorian Cancer Agency (334047, 112706). Funding Information: Dr Tonkin reported receiving research support or honoraria from Amgen, Boehringer- Ingelheim, Merck, and Pfizer, as well as materials in the ASPREE trial (Aspirin in Reducing Events in the Elderly) from Bayer. Dr Nelson reported receiving honoraria from Sanofi and Amgen, as well as Bayer for materials in ASPREE. Dr Reid reported being funded through a National Health and Medical Research Council Principal Research Fellowship. The other authors report no conflicts.",
year = "2022",
month = jun,
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.122.009511",
language = "English",
volume = "15",
journal = "Circulation: Heart Failure",
issn = "1941-3289",
publisher = "American Heart Association",
number = "6",
}